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Results: 5 of 8 patients are alive. Median follow-up was 8.5 
months. Two patients (25%) achieved tumor progression. In 
one patient (12%) complete response was observed, in two 
patients (25%) –stable disease, in three (38%) - partial 
response. Local control is 75%. In all was mild or moderate 
toxicity, which was fully treated by symptomatic therapy. 3 
of 8 patients died from further disease progression and 
metastatic process. 
Conclusions: The proposed method of fractionation in 
stereotactic body radiotherapy is effective, has medium 
toxicity and can be used in patients with inoperable 
pancreatic cancer. 
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Purpose/Objective: Patients with esophageal cancer not 
suitable for surgery, due to irresectability of the tumour or 
inoperability of the patient, can be treated with definitive 
chemoradiotherapy (dCRT) with curative intent. The purpose 
of this study is to evaluate the clinical outcomes of dCRT 
using Carboplatin and Paclitaxel. 
Materials and Methods: A retrospective cohort study was 
conducted in 2 collaborating institutes. Included patients 
were treated between January 2009 and December 2013, 
fulfilling the following criteria: primary squamous cell- or 
adenocarcinoma of the esophagus without signs of distant 
metastasis and treated with dCRT. Treatment consisted of 
external beam radiotherapy (28 fractions of 1.8 Gy) and 6 
weekly courses of Carboplatin (AUC 2) and Paclitaxel (50 
mg/m2). Survival, local and distant disease progression was 
recorded. Acute and late toxicity was scored according to the 
CTCAE v 4.0. For dysphagia scoring according to Knyrim was 
used. 
Results: Sixty-six patients were included, of whom 91% 
completed the radiotherapy and 82% received ≥ 80% of 
prescribed chemotherapy dose. Patient characteristics are 
shown in table 1. Median FU of patients alive was 26.6 
months. Median OS was 13.1 months (figure 1). Median PFS 
was 8.7 months. Eighteen patients (27%) had local 
progression and in total 27 patients (41%) developed distant 
metastasis. Two year OS, PFS and cumulative incidence of 
local progression were 30%, 23% and 26% respectively. In 
univariate analysis, tube feeding before start of dCRT and 
high dysphagia score were significant prognostic factors for 
worse OS. None of these factors were significant in 
multivariate analysis. Acute toxicity grade ≥ 3 was scored in 
47% of all patients. The majority was haematological toxicity 
grade 3-4, due to low blood counts. Only 3% had a severe 
infectious adverse event. 18% of patients had acute 
gastrointestinal toxicity. Late adverse events grade ≥ 3 were 
seen in 20% of all patients, most events were esophageal 
stenoses. There were two treatment related deaths. Of the 
46 patients with available data on dysphagia score at 3 
months, 70% had a better dysphagia score than before dCRT. 
Of 30 patients with tube feeding during treatment, only 4 
patients still required tube feeding 3 months after dCRT. 
  
 





Conclusions: Definitive chemoradiotherapy using Carboplatin 
and Paclitaxel for inoperable esophageal cancer led to 
symptom relieve and a median overall survival of 13 months. 
Although acute toxicity grade ≥ 3 was common, the majority 
of patients were able to finish treatment. Given the toxicity 
profile and relatively short median survival, adequate 
selection of patients for this intensive treatment is required. 
In addition, as local recurrence rate was high, further dose 
escalation may be beneficial.  
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Purpose/Objective : Response evaluation of anal canal 
neoplasm after Radiochemotherapy (RCT) represents a 
significant problem correlated to the tumour slow regression 
and to difficulties in response interpretation. Recent findings 
indicate that a complete clinical response occurs in the 
majority of patients within 6 months from the end of RCT, 
even if tumour regression may be slower.  
The aim of this study was to define the optimal time to 
assess complete response following RCT.  
Materials and Methods: Twenty-four patients (pts) (7 male, 
17 female; median age 58 years, range 42 to 85; 15 T1-T2, 9 
T3-T4, 12 N+) affected by epidermoid anal canal carcinoma, 
all HIV-, were treated with RCT (FUMIR) between November 
2005 and July 2012. Total dose at primary tumor ranged from 
45 to 65 Gy with a median of 59.4 Gy, 1.8 Gy fraction. After 
treatment pts were evaluated with DRE (by the same 
physicians GM and FC) and with serial EAUS carried out by the 
same operator (RG), every month in the first 4 months, and 
then every two months up to 1 year. Abdominal-pelvis MRI 
was performed at 3, 6 and 12 months. Median follow up was 
34 months (range 10-80). A complete response to therapy was 
defined as no clinically detectable disease (or residual scar) 
at DRE and a reduced mass with a stable hyperechogenic 
images at EAUS . 
Results: Complete Response (CR) to therapy was seen in 21 
pts (87.5%). Progressive disease occurred in 3 pts: 2 pts 
performed salvage surgery and 1 patient received 
chemotherapy for concomitant distant metastasis. Among the 
responders (21), only 6 ( 28.6 % ) had CR at 4 months. At 6 
months (time suggested by guidelines for a final evaluation) 
only half patients ( 11/21) had a complete regression. All the 
CR were obtained within 14 months. 
Conclusions: In our experience, extending the evaluation 
time over 1 year, 10 patients with CR between 8 and 14 
months avoided an unnecessary demolitive surgery. A final 
evaluation at 6 months to address patient to a salvage 
surgery could be inappropriate for late responder patients. 
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Purpose/Objective: It is still controversial if changes in 
18FDG-PET/CT after neoadjuvant treatments for rectal cancer 
could predict pathological response. In this preliminary 
report, we analyzed changes of several 18FDG-PET/CT 
parameters obtained before and after neoadjuvant 
treatments for locally advanced rectal cancer.  
Materials and Methods: Twelve locally advanced rectal 
cancer patients consecutively enrolled in a prospective 
institutional trial were analyzed. All these patients 
underwent whole body MRI and 18FDG-PET/CT before and 
after neoadjuvant treatments for initial staging and for 
restaging before surgery. Nine patients received long-course 
chemoradiotherapy (45 Gy on pelvic nodes and mesorectum 
and 50 Gy on gross tumor volume and corresponding 
mesorectum, delivered with a simultaneous integrated boost) 
and 3 patients a short-course radiotherapy (25 Gy in 5 
fractions delivered on pelvic nodes and mesorectum). All 
patients were treated with helical tomotherapy and daily 
image guided radiotherapy, and all of them underwent 
radical surgery. 18FDG-PET/CT studies were integrated in the 
Velocity© software. A standardized uptake value (SUV) > 3 
was used as threshold to automatically contour the rectal 
gross tumor volume on the pre-treatment 18FDG-PET/CT. 
Then, this volume was projected on the post-treatment 
PET/CT, after a deformable image fusion of the pre- and 
post-therapy exams. We analyzed variations in terms of 
SUVmax, SUVmin, SUVmean in this area and compared them to 
final pathological response evaluated with the Mandard 
tumor regression grade (TRG). 
Results: Despite important variations in the studied PET/CT 
parameters, most of the patients presented the same TRG = 3 
(7/12 patients). Moreover, we also noted that some patients 
presenting different trends in metabolic responses were 
finally classified as TRG = 3 patients. Nevertheless, linear 
